Cargando…

Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation

BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for anti-Pneumocystis jirovecii pneumonia (PcP) prophylaxis in kidney transplant recipients (KTR). Post-transplant management balances preventing PcP with managing TMP-SMX-related adverse effects. TMP-SMX dose reduction addres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prasad, G. V. Ramesh, Beckley, Jill, Mathur, Mohit, Gunasekaran, Madhushankar, Nash, Michelle M., Rapi, Lindita, Huang, Michael, Zaltzman, Jeffrey S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451305/ https://www.ncbi.nlm.nih.gov/pubmed/30953458 http://dx.doi.org/10.1186/s12879-019-3944-0

Ejemplares similares

Lifelong Prophylaxis With Trimethoprim-Sulfamethoxazole for Prevention of Outbreak of Pneumocystis jirovecii Pneumonia in Kidney Transplant Recipients
por: Goto, Norihiko, et al.
Publicado: (2017)

A Case of Pneumonia Caused by Pneumocystis jirovecii Resistant to Trimethoprim-Sulfamethoxazole
por: Lee, Sang Min, et al.
Publicado: (2015)

Efficacy of Low-Dose Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jirovecii Pneumonia in Deceased Donor Kidney Recipients
por: Ji, Jianlei, et al.
Publicado: (2021)

Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review
por: Haseeb, Abdul, et al.
Publicado: (2022)

401. Pneumocystis jirovecii Pneumonia in Renal Transplant Recipients After a 6-Month Trimethoprim–Sulfamethoxazole Prophylaxis: A Case–Control Study
por: Park, Se Yoon, et al.
Publicado: (2018)

807. Trimethoprim/Sulfamethoxazole for Pneumocystis jirovecii pneumonia prophylaxis in B-cell lymphoma: A multicenter randomized double-blinded placebo-controlled trial
por: Angsutararux, Taksaon, et al.
Publicado: (2023)

Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies
por: Hammarström, Helena, et al.
Publicado: (2022)

Impact of an Intravenous Trimethoprim/Sulfamethoxazole Shortage on Treatment Outcomes Among HIV-Infected Patients with Pneumocystis jirovecii Pneumonia
por: Dilworth, Thomas J., et al.
Publicado: (2014)

Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant
por: Chapman, Fiona A., et al.
Publicado: (2019)

Treatment of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus-infected patients using a combination of trimethoprim-sulfamethoxazole and caspofungin
por: Wu, Huan-Huan, et al.
Publicado: (2022)

Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality
por: Song, Siyang, et al.
Publicado: (2022)

Multicenter Study of Trimethoprim/Sulfamethoxazole-Related Hepatotoxicity: Incidence and Associated Factors among HIV-Infected Patients Treated for Pneumocystis jirovecii Pneumonia
por: Yang, Jen-Jia, et al.
Publicado: (2014)

Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia
por: Koshy, Robin, et al.
Publicado: (2019)

An open-label, randomized controlled trial of sulfamethoxazole–trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up
por: Utsunomiya, Masako, et al.
Publicado: (2020)

Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial
por: Sohani, Zahra N., et al.
Publicado: (2022)

A Case of a Pneumocystis Pneumonia Twenty-four Years After Living Kidney Transplantation Due to Withdrawal of Sulfamethoxazole/Trimethoprim Prophylaxis
por: Kono, Momoko, et al.
Publicado: (2018)

Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice
por: Lobo, Maria Luísa, et al.
Publicado: (2013)

Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole used as First-Line Treatment for Pneumocystis jirovecii Pneumonia
por: Kim, Tark, et al.
Publicado: (2018)

Nonadherence to Primary Prophylaxis against Pneumocystis jirovecii Pneumonia
por: Heffelfinger, James D., et al.
Publicado: (2009)

Epidemiology of Pneumocystis jirovecii Pneumonia and (Non-)use of Prophylaxis
por: Dunbar, Albert, et al.
Publicado: (2020)

Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazole
por: Park, Jun Won, et al.
Publicado: (2019)

A Pilot Study of Echinocandin Combination with Trimethoprim/Sulfamethoxazole and Clindamycin for the Treatment of AIDS Patients with Pneumocystis Pneumonia
por: Wang, Mengyan, et al.
Publicado: (2019)

Prolonged and recurrent hypoglycemia induced by trimethoprim-sulfamethoxazole in a Hodgkin lymphoma patient with Pneumocystis carinii pneumonia
por: Wang, Bing-Jie, et al.
Publicado: (2021)

Pneumocystis jirovecii Pneumonia Prophylaxis for Cancer Patients during Chemotherapy
por: Takeuchi, Kazuto, et al.
Publicado: (2021)

Methemoglobinemia in a Pediatric Oncology Patient Receiving Sulfamethoxazole/Trimethoprim Prophylaxis
por: Carroll, Timothy G., et al.
Publicado: (2016)

1592. Safety of Oral Trimethoprim/Sulfamethoxazole Prophylaxis in Renal Transplant Recipients
por: Horvat, Courtney, et al.
Publicado: (2018)

Efficacy of using trimethoprim‐sulfamethoxazole prophylaxis in an adult patient with autoimmune neutropenia
por: Azuma, Naoto, et al.
Publicado: (2019)

Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study
por: Yamashita, Kanae, et al.
Publicado: (2021)

Sulfamethoxazole-Trimethoprim and Hyperkalemia in an Infant
por: Hudzik, Samantha A., et al.
Publicado: (2020)

Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids
por: Park, Jun Won, et al.
Publicado: (2018)

Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations
por: Mori, Shunsuke, et al.
Publicado: (2015)

Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis
por: Andreasen, Philip B., et al.
Publicado: (2021)

A retrospective study of patients with systemic lupus erythematosus combined with Pneumocystis jiroveci pneumonia treated with caspofungin and trimethoprim/sulfamethoxazole
por: Wang, Zhi-Guo, et al.
Publicado: (2019)

145. the Efficacy and Safety of Low Dose Trimethoprim-sulfamethoxazole for the Treatment of Pneumocystis Pneumonia: A Systematic Review and Meta-analysis
por: Tritle, Brandon, et al.
Publicado: (2020)

Preliminary Study on the Combination Effect of Clindamycin and Low Dose Trimethoprim-Sulfamethoxazole on Severe Pneumocystis Pneumonia After Renal Transplantation
por: Gu, Zhun-Yong, et al.
Publicado: (2022)

Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”
por: Lee, Chang-Hoon
Publicado: (2018)

Trimethoprim/sulfamethoxazole resistance in Burkholderia pseudomallei
por: Dance, D.A.B., et al.
Publicado: (2014)

No Statistically Apparent Difference in Antifungal Effectiveness Observed Among Trimethoprim/Sulfamethoxazole Plus Clindamycin or Caspofungin, and Trimethoprim/Sulfamethoxazole Monotherapy in HIV-Infected Patients with Moderate to Severe Pneumocystis Pneumonia: Results of an Observational Multicenter Cohort Study
por: Huang, Yinqiu, et al.
Publicado: (2022)

Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”
por: Kim, Tark, et al.
Publicado: (2018)

Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim–sulfamethoxazole: lessons from an observational cohort study
por: Creemers-Schild, Dina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1fl646g4hfea5mrq945ihmnqdo